OncoMatch/Clinical Trials/NCT06536959
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Is NCT06536959 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine for relapsed acute myeloid leukemia.
Treatment: PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine — The efficiency and safety of PD-1 inhibitor in combination with venetoclax and hypomethylation agent in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome remain uncertain. In this study, the investigators aimed to assess safety and response to a new PD-1 inhibitor-based triple-drug combination regimen (venetoclax + hypomethylation agent + PD-1 inhibitor) in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome patients, or who had positive minimal residual disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: induction chemotherapy
Patients who did not respond or had disease recurrence after 1 course of induction chemotherapy or had positive immune residues after induction chemotherapy or positive molecular residues (if any) after induction chemotherapy
Cannot have received: major surgery
Major surgery...within 2 weeks of the first medication
Cannot have received: radiotherapy
radiotherapy...within 2 weeks of the first medication
Cannot have received: chemotherapy
chemotherapy...within 2 weeks of the first medication
Cannot have received: biological therapy
biological therapy...within 2 weeks of the first medication
Cannot have received: immunotherapy
immunotherapy...within 2 weeks of the first medication
Cannot have received: experimental therapy
experimental therapy...within 2 weeks of the first medication
Lab requirements
Kidney function
creatinine≤2×uln
Liver function
alt and ast ≤2×uln; bilirubin≤2×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify